for a Site Initiation Visit

A well-structured SIV agenda ensures full understanding of study expectations. A typical SIV agenda includes:

1. Welcome and introductions
2. Study overview and objectives
3. Protocol training and discussion
4. Safety reporting and adverse event handling
5. Informed consent process and documentation
6. Subject eligibility criteria and screening
7. Visit schedule and procedures
8. CRF/eCRF completion guidelines
9. IP storage, handling, and accountability procedures
10. Monitoring plans and CRA contact info
11. Review of site-specific responsibilities and expectations
12. Q&A and SIV acknowledgment forms

Training the Site Team

Effective SIVs ensure all relevant staff receive protocol-specific training. Best practices include:

• Training logs signed by every staff member who will work on the study
• Review of GCP obligations and regulatory expectations
• Interactive protocol training with case scenarios and discussion
• Demonstration of systems like EDC, IWRS, ePRO using sponsor login credentials
• Role clarification for PI, sub-I, study coordinator, pharmacist, and lab personnel

Site Documentation for SIV

Before activation, the site must provide and file the following documents in the ISF:

• IRB/EC approval letter
• Signed Investigator Agreement or FDA Form 1572
• PI and sub-I CVs and medical licenses
• GCP training certificates (dated within 2 years)
• Financial Disclosure Forms
• Site Delegation Log signed by PI
• Equipment calibration certificates
• Temperature logs for IP storage areas

Investigational Product (IP) Setup and Verification

Before the SIV or during the visit, verify the following:

• IP shipment tracking and receipt readiness
• IP storage conditions (e.g., 2–8°C refrigerator with backup power and alarm)
• Temperature logbooks and excursion SOPs
• Pharmacy staff understanding of blinded/unblinded roles if applicable

Confirm that accountability logs and drug destruction SOPs are ready per GMP compliance guidelines.

Technology and System Access Readiness

The SIV should ensure that all required systems are live and staff are trained:

• EDC login credentials and password policies
• Randomization and drug assignment via IWRS/IRT
• ePRO or patient diary setup, if applicable
• Central lab portal access for sample tracking

All systems must be tested, and access verified before subject enrollment begins.

CRA Role During the SIV

The Clinical Research Associate (CRA) must:

• Lead or co-lead the training sessions
• Ensure site documentation and staff training are completed
• Verify essential documents for completeness and accuracy
• Answer questions related to the protocol, monitoring plan, and communication expectations
• Sign off on the Site Initiation Report

CRAs may also conduct a mock patient visit simulation or protocol walk-through.

Common Pitfalls to Avoid

• Missing signatures on training logs
• Staff unfamiliar with key protocol procedures or visit windows
• Site lacks access to critical systems (EDC, IWRS)
• IP storage conditions not validated or missing calibration logs
• Regulatory documents incomplete or expired

Post-SIV Follow-Up and Activation

• CRA submits Site Initiation Visit Report to sponsor within 5 business days
• Site submits final regulatory package to sponsor and TMF
• Sponsor/CRO issues green light for enrollment
• Trial site begins subject screening as per approved start date

Conclusion

Thorough preparation and structured execution of the Site Initiation Visit are essential to ensuring clinical trial readiness. A well-conducted SIV boosts protocol adherence, accelerates recruitment, and strengthens data quality from the outset. By aligning staff, documentation, technology, and training before activation, sponsors and CROs can launch studies confidently and compliantly.